Table 2.
Completed clinical trials of SGLT2i in patients with T2DM, CVD or both
| Drugs | Trials | Patients | Median follow-up | Outcomes | References | |||
|---|---|---|---|---|---|---|---|---|
| 3-Point MACE | CV Death | HHF | CV Death or HHF | |||||
| Empagliflozin | EMPA-REG | 7,020 T2DM patients with CVD. | 3.1 years | 0.86 (0.74-0.99) * | 0.62 (0.49-0.77) * | 0.65 (0.50-0.85) * | 0.66 (0.55-0.79) * | 9 |
| EMPEROR-Reduced | 3,600 patients with HF and reduced ejection fraction (≤40%). |
16 months | —— | —— | 0.70 (0.58-0.85) * | 0.75 (0.65-0.86) * | 30 | |
| Canagliflozin | CANVAS | 10,142 T2DM patients with CVD or CV risk factors. | 2.4 years | 0.86 (0.75-0.97) * | 0.87 (0.72-1.06) | 0.67 (0.52-0.87) * | —— | 33 |
| CREDENCE | 4,401 T2DM patients with CKD. | 2.6 years | 0.80 (0.67-0.95) * | —— | 0.61 (0.47-0.80) * | —— | 35 | |
| Dapagliflozin | DECLARE-TIMI 58 | 17,160 T2DM patients with ASCVD or CV risk factors. | 4.2 years | 0.93 (0.84-1.03) | 0.98 (0.82-1.17) | 0.73 (0.61-0.88) * | 0.83 (0.73-0.95) | 36 |
| DAPA - HF | 4,744 patients with HF and reduced ejection fraction. | 18.2 months | —— | 0.82 (0.69-0.98) | 0.70 (0.59-0.83) | 0.75 (0.65-0.85) * | 38 | |
| Ertugliflozin | VERTIS-CV | 8,246 T2DM patients with ASCVD. | 3.5 years | 0.97 (0.85-1.11) | 0.92 (0.77-1.11) | 0.70 (0.54-0.90) | —— | 40 |
ASCVD: atherosclerotic cardiovascular diseases; CKD: chronic kidney disease; CV: cardiovascular; CVD: cardiovascular diseases; HF: heart failure; HHF: hospitalization for heart failure; MACE: major adverse cardiovascular events; T2DM: type 2 diabetes mellitus; "*" statistically significant difference.